冠状动脉内注射重组人尿激酶原在STEMI患者急诊PCI中的应用效果  

Application effect of intracoronary injection of recombinant human prourokinase in emergency PCI of STEMI patients

作　　者：黄芯芯 仇昌智[1] 檀开宇 徐冬 梁栋 林利萍[1] HUANG Xinxin;QIU Changzhi;TAN Kaiyu;XU Dong;LIANG Dong;LIN Liping(the Second People's Hospital of Qinzhou,Qinzhou 535000,China)

机构地区：[1]钦州市第二人民医院,广西钦州535000

出　　处：《临床医学研究与实践》2025年第11期54-57,共4页Clinical Research and Practice

基　　金：广西壮族自治区卫生健康委自筹经费科研课题(No.Z-N20231888);钦州市科学研究与技术开发计划项目(No.20233108)。

摘　　要：目的探讨冠状动脉内注射重组人尿激酶原在急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中的应用效果。方法选取接受PCI治疗的118例STEMI患者,以随机数字表法将其分为对照组(59例,生理盐水+PCI治疗)、试验组(59例,冠状动脉内注射重组人尿激酶原+PCI治疗)。比较两组的治疗效果。结果术后,试验组的心肌梗死溶栓治疗(TIMI)血流分级优于对照组,校正的TIMI血流帧数(CTFC)低于对照组,ST段回落≥70%占比高于对照组(P<0.05)。术后,试验组的肌酸激酶(CK)、肌酸激酶同功酶-MB(CK-MB)及心肌肌钙蛋白I(cTnI)水平均低于对照组(P<0.05)。术后,试验组的左心室射血分数(LVEF)大于对照组,左心室舒张末期内径(VEDD)、左心室收缩末期内径(LVESD)短于对照组(P<0.05)。两组的主要不良心血管事件(MACE)总发生率、出血并发症总发生率无显著差异(P>0.05)。结论冠状动脉内注射重组人尿激酶原在STEMI患者急诊PCI中具有显著疗效。Objective To investigate the application effect of intracoronary injection of recombinant human prourokinase in emergency percutaneous coronary intervention(PCI)in patients with acute ST-segment elevation myocardial infarction(STEMI).Methods A total of 118 STEMI patients undergoing PCI were selected and divided into control group(59 cases,physiological saline+PCI treatment)and experimental group(59 cases,intracoronary injection of recombinant human prourokinase+PCI treatment)by random number table method.The therapeutic effects of the two groups were compared.Results After operation,the thrombolysis in myocardial infarction(TIMI)blood flow grade in the experimental group was better than that in the control group,the corrected TIMI frame count(CTFC)was lower than that in the control group,and the proportion of ST segment reduction≥70%was higher than that in the control group(P<0.05).After operation,the levels of creatine kinase(CK),creatine kinase isoenzyme-MB(CK-MB)and cardiac troponin I(cTnI)in the experimental group were lower than those in the control group(P<0.05).After operation,the left ventricular ejection fraction(LVEF)in the experimental group was higher than that in the control group,and the left ventricular end-diastolic diameter(VEDD)and left ventricular end-systolic diameter(LVESD)were shorter than those in the control group(P<0.05).There were no significant differences in the total incidence of major adverse cardiovascular events(MACE)and the total incidence of bleeding complications between the two groups(P>0.05).Conclusion Intracoronary injection of recombinant human prourokinase in emergency PCI in STEMI patients has a significant effect.

关 键 词：重组人尿激酶原 急性ST段抬高型心肌梗死 经皮冠状动脉介入治疗 

分 类 号：R542.22[医药卫生—心血管疾病]